Official ESCRS | European Society of Cataract & Refractive Surgeons
Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Posters

Search Title by author or title

Toric intraocular lens implantation after corneal transplantation

Poster Details

First Author: L.Modis HUNGARY

Co Author(s):    A. Rentka   A. Kemeny-Beke                 

Abstract Details

Purpose:

To demonstrate experiences and results of toric intraocular lens (IOL) implantation after penetrating keratoplasty in patients with astigmatism and cataract.

Setting:

Department of Ophthalmology, University of Debrecen, Debrecen, Hungary

Methods:

Twelve eyes of 12 patients (mean age 42�Â�±12.6) with more than 3.5 diopters (D) astigmatism following penetrating keratoplasty were included in this retrospective study. Indications for corneal transplantation were keratoconus n=8, metaherpetic keratitis n=2, corneal dystrophy n=2. Suture removal was performed after 6 months, phacoemulsification with toric IOL implantation (cylindrical diopter range 1.5D-12D) was done after 37 months in average after keratoplasty. Visual acuity, topographic keratometry measurements and detailed ophthalmic examinations were performed in every patient. The mean follow-up was 9 months.

Results:

Corrected distant visual acuity (CDVA) improved continuously from 0.19 to 0.84 (p<0.0001) at the end of the follow-up period. Seven patients (58%) disclosed 0.9-1.0 distant visual acuity without correction. Spherical correction was necessary in 4 cases (33%) with the absolute mean of 1.75D. Average manifest cylindrical refraction reduced from 3.89D to 1.81D (p=0.02). Topographic astigmatism was 7.0D before surgery and changed to 5.6D (p=0.3). One patient complained about glare vision. All transplants remained clear and transparent.

Conclusions:

Toric IOL implantation is one of the effective, predictable, and safe procedure to simultaneously solve astigmatism and cataract in patients after corneal transplantation.

Financial Disclosure:

NONE

Back to Poster listing